Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: A meta-analysis of randomized controlled trials

European Journal of Clinical Pharmacology

Volumn 69, Issue 2, 2013, Pages 151-159

  Xiao, Yong Ying ^a   Zhan, Ping ^b   Yuan, Dong Mei ^a   Liu, Hong Bing ^a   Lv, Tang Feng ^a   Song, Yong ^a   Shi, Yi ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING CHEST HOSPITAL   (China)

Author keywords

Chemotherapy; Meta analysis; Multitargeted antiangiogenic TKI; Non small cell lung cancer; RCTs

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; CEDIRANIB; DOCETAXEL; NINTEDANIB; PACLITAXEL; PAZOPANIB; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VANDETANIB;

ADVANCED CANCER; ALOPECIA; ANOREXIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84873713565     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1333-3     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Alberg A, Ford J, Samet J (2007) Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines. Chest 132:29S-55S
3. Stinchcombe TE, Socinski MA (2009) Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 6:233-241
4. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103 (Pubitemid 30324363)
5. Fossella FV, De Vore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362 (Pubitemid 30415821)
6. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597 (Pubitemid 41079796)
7. Molina JR, Yang P, Cassivi SD et al (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584-594 (Pubitemid 351720831)
8. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550 (Pubitemid 44917502)
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132 (Pubitemid 41058344)
10. Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818
11. Pennell NA, Mekhai T (2009) Investigational agents in the management of non-small cell lung cancer. Curr Oncol Rep 11:275-284
12. Ciardiello F, Troiani T, Bianco R et al (2006) Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: A rational approach for multitarget anticancer therapy. Ann Oncol 17:vii109-vii114 (Pubitemid 43985191)
13. Naumov GN, Nilsson MB, Cascone T et al (2009) Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 15:3484-3494
14. Pennell NA, Lynch TJ (2009) Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14:399-411
15. Ivy SP, Wick JY, Kaufman BM (2009) An overview of small molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6:569-579
16. Ulahannan SV, Brahmer JR (2011) Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest 29(4):325-337
17. Herbst RS, Sun Y, Eberhardt WE et al (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11:619-626
18. de Boer RH, Arrieta O, Yang CH et al (2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 29:1067-1074
19. Heymach JV, Paz-Ares L, De Braud F et al (2008) Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26:5407-5415
20. Heymach JV, Johnson BE, Prager D et al (2007) Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25:4270-4277 (Pubitemid 47548567)
21. Scagliotti G, Novello S, von PJ et al (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28:1835-1842
22. Goss GD, Arnold A, Shepherd FA et al (2010) Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28:49-55
23. Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17:1-12 (Pubitemid 26120810)
24. Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315:629-634 (Pubitemid 27387172)
25. Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69[Suppl 3]:4-10 (Pubitemid 41680947)
26. Bremnes RM, Camps C, Sirera R (2006) Angiogenesis in non-small cell lung cancer: the prognostic impact of neo angiogenesis and the cytokines VEGF and bFGF in tumors and blood. Lung Cancer 51:143-158 (Pubitemid 43144358)
27. Grzegorz Korpanty G, Smyth E, Sullivan LA (2010) Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp Biol Med 235:3-9
28. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad-spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109 (Pubitemid 39331023)
29. Nikolinakos P, Heymach JV (2008) The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. JThorac Oncol 3[6 Suppl 2]:S131-S134 (Pubitemid 351786743)
30. Herbst RS (2006) Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer 8[Suppl 1]:S23-S30
31. Ricciardi S, Tomao S, de Marinis F (2009) Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10:28-35